Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency

Cell(2024)10.1016/j.cell.2023.12.025Source: DataRank Database

SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency is a research paper published in Cell (2024). On theSindex it has a DataRank of 3.2. It has been cited 122 times, with 103 citing works in its 1-hop citation network.

N/A

3.2DataRank · unranked

Scored on demand from live citation data

Open Access122 citations · 103 citing works in its network

Download PDF

Cite:

Linked data & code

cellosaurus doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)Impact (FWCI 36.45)OA: greenTopics (45)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 22%Citation Network 78%

Base Score Contribution

0.722

From this paper's citation signal

Citation Network Contribution

2.5

From 69 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 103 citers.

SARS‐CoV‐2 Omicron subvariants from BA.2 to BA.2.86 and JN.1: strong lung infection ability and evolving immune escape capacity
MedComm20244 citations5 referencesContributes 0.322
SARS-CoV-2 evolution from the BA.2.86 to JN.1 variants: unexpected consequences
Trends in Immunology202452 citations14 referencesContributes 0.284
Deletion of V483 in the spike confers evolutionary advantage on SARS-CoV-2 for human adaptation and host-range expansion after a prolonged pandemic
Cell Research20246 citations9 referencesContributes 0.216
Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion
mBio202450 citations32 referencesContributes 0.123
A Paradigm Shift: The Reclassification of SARS-CoV-2 and Longitudinal Immune Responses in Japanese Healthcare Workers
COVID20241 citations6 referencesContributes 0.116

Authors (18)

Amy Kempf,Inga Nehlmeier ORCID,Anne Cossmann ORCID,Anja Richter ORCID,Najat Bdeir ORCID

Live enrichment

PubMed:38194966 PMC:PMC11317634 OpenAlex:https://openalex.org/W4390674306

Institut Pasteur

Grant: 101102733

Horizon Europe

Grant: 101057100

The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infection: Towards personalised medicine

Bundesministerium für Bildung und Forschung

Grant: 01KX2021

Bundesministerium für Bildung und Forschung

Grant: 01KI2043

China Scholarship Council

Grant: 202006270031

Niedersächsisches Ministerium für Wissenschaft und Kultur

Grant: 4LZF23

Deutsche Forschungsgemeinschaft

Grant: RTG1660

Deutsche Forschungsgemeinschaft

Grant: TRR130

Deutsche Forschungsgemeinschaft

Grant: PO 716/11-1

European Commission

Grant: 10FF22

European Commission

Grant: 7FF22

Deutsches Zentrum für Infektionsforschung

Grant: 80018019238

National Institutes of Health

Grant: U01AI151758

Deutsche Forschungsgemeinschaft

Grant: unidentified

unidentified

European Regional Development Fund

Lower Saxony State Ministry of Science and Culture

Bavarian Research Foundation

FWCI

36.45

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

greenLicense: Elsevier Non-Commercial

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11317634/pdf/nihms-2013173.pdf

publisherhttps://api.elsevier.com/content/article/PII:S0092867423013995?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0092867423013995?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11317634

Fields of Study

SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingCOVID-19 Clinical Research Studies0301 basic medicine03 medical and health sciences

MeSH Terms

COVID-19SARS-CoV-2Antibodies, ViralHumansLungCaspasesVirus InternalizationAntibodies, NeutralizingSpike Glycoprotein, Coronavirus

Keywords

BiologyInfectivityVirologyAntibodyNeutralizationVirusProteasesNeutralizing antibodyViral entryCoronavirusImmunologyCoronavirus disease 2019 (COVID-19)Viral replicationFusionSpike proteinMutationsTmprss2Antibody EvasionSars-cov-2Ba.2.86Lung Cell EntryPirola VariantCOVID-19Virus InternalizationAntibodies, ViralAntibodies, Neutralizing[SDV] Life Sciences [q-bio]CaspasesSpike Glycoprotein, CoronavirusHumansLung

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-beingSDG 0: Partnerships for the goals